QRS prolongation is associated with high defibrillation thresholds during cardioverter-defibrillator implantations in patients with hypertrophic cardiomyopathy

Circulation Journal

Volumn 73, Issue 6, 2009, Pages 1028-1032

  Nagai, Takayuki ^a   Kurita, Takashi ^a   Satomi, Kazuhiro ^a   Noda, Takashi ^a   Okamura, Hideo ^a   Shimizu, Wataru ^a   Suyama, Kazuhiro ^a   Aihara, Naohiko ^a   Kobayashi, Junjiro ^a   Kamakura, Shiro ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Defibrillation threshold; Hypertrophic cardiomyopathy; Implantable cardioverter defibrillator; QRS prolongation

Indexed keywords

AMIODARONE; DISOPYRAMIDE; MEXILETINE; SOTALOL;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEFIBRILLATION; DEFIBRILLATION THRESHOLD; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; HEART FIBRILLATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTATION; MALE; PREDICTOR VARIABLE; QRS COMPLEX; QRS PROLONGATION; RETROSPECTIVE STUDY; SINUS RHYTHM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; DEFIBRILLATORS, IMPLANTABLE; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TACHYCARDIA, VENTRICULAR; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FIBRILLATION; YOUNG ADULT;

EID: 67649843992     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0744     Document Type: Article

References (34)

1. Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 365-373. (Pubitemid 30084534)
2. Maron BJ, Estes NA 3rd, Maron MS, Almquist AK, Link MS, Udelson JE. Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. Circulation 2003; 107: 2872-2875.
3. Begley DA, Mohiddin SA, Tripodi D, Winkler JB, Fananapazir L. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003; 26: 1887-1896. (Pubitemid 37130061)
4. Lee CH, Nam GB, Park HG, Kim HY, Park KM, Kim J, et al. Effects of antiarrhythmic drugs on inappropriate shocks in patients with implantable cardioverter defibrillators. Circ J 2008; 72: 102-105.
5. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45: 1251-1258. (Pubitemid 40523146)
6. Hamada M, Shigematsu Y, Ikeda S, Hara Y, Okayama H, Kodama K, et al. Class Ia antiarrhythmic drug cibenzoline: A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997; 96: 1520-1524. (Pubitemid 27375346)
7. Hamada M, Shigematsu Y, Inaba S, Aono J, Ikeda S, Watanabe K, et al. Antiarrhythmic drug cibenzoline attenuates left ventricular pressure gradient and improves transmitral Doppler flow pattern in patients with hypertrophic obstructive cardiomyopathy caused by midventricular obstruction. Circ J 2005; 69: 940-945. (Pubitemid 41124262)
8. Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93: 841-842.
9. Neuzner J, Liebrich A, Jung J, Himmrich E, Pitschner HF, Winter J, et al. Safety and efficacy of implantable defibrillator therapy with programmed shock energy at twice the augmented step-down defibrillation threshold: Results of the prospective, randomized, multicenter Low-Energy Endotak Trial. Am J Cardiol 1999; 83: 34D-39D. (Pubitemid 29125069)
10. Rashba EJ, Olsovsky MR, Shorofsky SR, Kirk MM, Peters RW, Gold MR. Temporal decline in defibrillation thresholds with an active pectoral lead system. J Am Coll Cardiol 2001; 38: 1150-1155. (Pubitemid 32912725)
11. Sahn DJ, DeMaria A, Kisslo J, Weyman A (the Committee on M-Mode Standardization of the American Society for Echocardiography). Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083. (Pubitemid 9091990)
12. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic vatidation of the method. Circulation 1977; 55: 613-618. (Pubitemid 8066109)
13. Babbs CF. Alteration of defibrillation threshold by antiarrhythmic drugs: A theoretical framework. Crit Care Med 1981; 9: 362-363.
14. Hamada M, Shigematsu Y, Hara Y, Suzuki M, Ohtsuka T, Hiasa G, et al. Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy. Jpn Circ J 2001; 65: 531-538. (Pubitemid 32531547)
15. Hamada M, Aono J, Ikeda S, Watanabe K, Inaba S, Suzuki J, et al. Effect of intravenous administration of cibenzoline on left ventricular diastolic pressures in patients with hypertrophic cardiomyopathy: Its relationship to transmitral Doppler flow profiles. Circ J 2007; 10: 1540-1544. (Pubitemid 47529653)
16. Gold MR, Khalighi K, Kavesh NG, Daly B, Peters RW, Shorofsky SR. Clinical predictors of transvenous biphasic defibrillation thresholds. Am J Cardiol 1997; 79: 1623-1627. (Pubitemid 27339471)
17. Pinski SL, Vanerio G, Castle LW, Morant VA, Simmons TW, Trohman RG, et al. Patients with a high defibrillation threshold: Clinical characteristics, management, and outcome. Am Heart J 1991; 122: 89-95.
18. Reiffel JA, Coromilas J, Zimmerman JM, Spotnitz HM. Drug-device interactions: Clinical considerations. Pacing Clin Electrophysiol 1985; 8: 369-373. (Pubitemid 15095512)
19. Yoon MS, Han J. Electrophysiologic effects of mexiletine on normal and ischemic ventricles. J Electrocardiol 1982; 15: 109-113. (Pubitemid 12159582)
20. Marinchak RA, Friehling TD, Kline RA, Stohler J, Kowey PR. Effect of antiarrhythmic drugs on defibrillation threshold: Case report of an adverse effect of mexiletine and review of the uterature. Pacing Clin Electrophysiol 1988; 11: 7-12. (Pubitemid 18030720)
21. Khalighi K, Daly B, Leino EV, Shorofsky SR, Kavesh NG, Peters RW, et al. Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol 1997; 79: 150-153. (Pubitemid 127673701)
22. Pelosi F Jr, Oral H, Kim MH, Sticherling C, Horwood L, Knight BP, et al. Effect of chronic amiodarone therapy on defibrillation energy requirements in humans. J Cardiovasc Electrophysiol 2000; 11: 741-743.
23. Kopp DE, Blakeman BP, Kall JG, Olshansky B, Kinder CA, Wilber DJ. Predictors of defibrillation energy requirements with nonepicardial lead systems. Pacing Clin Electrophysiol 1995; 18: 253-260.
24. Anastasiou-Nana MI, Tsagalou EP, Charitos C, Siafakas KX, Drakos S, Terrovitis JV, et al. Effects of transient myocardial ischemia on the ventricular defibrillation threshold. Pacing Clin Electrophysiol 2005; 28: 97-101. (Pubitemid 40344119)
25. Babbs CF, Paris RL, Tacker WA Jr, Bourland JD. Effects of myocardial infarction on catheter defibrillation threshold. Med Instrum 1983; 17: 18-20.
26. Qin H, Walcott GP, Killingsworth CR, Rollins DL, Smith WM, Ideker RE. Impact of myocardial ischemia and reperfusion on ventricular defibrillation patterns, energy requirements, and detection of recovery. Circulation 2002; 105: 2537-2542. (Pubitemid 34568977)
27. Walcott GP, Killingsworth CR, Smith WM, Ideker RE. Biphasic waveform external defibrillation thresholds for spontaneous ventricular fibrillation secondary to acute ischemia. J Am Coll Cardiol 2002; 39: 359-365. (Pubitemid 34084646)
28. Strobel JS, Kenknight BH, Rollins DL, Smith WM, Ideker RE. The effects of ventricular fibrillation duration and site of initiation on the defibrillation threshold during early ventricular fibrillation. J Am Coll Cardiol 1998; 32: 521-527. (Pubitemid 28397741)
29. Windecker S, Ideker RE, Plumb VJ, Kay GN, Walcott GP, Epstein AE. The influence of ventricular fibrillation duration on defibrillation efficacy using biphasic waveforms in humans. J Am Coll Cardiol 1999; 33: 33-38. (Pubitemid 29064069)
30. Hodgson DM, Olsovsky MR, Shorofsky SR, Daly B, Gold MR. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol 2002; 25: 408-413. (Pubitemid 34438242)
31. Chapman PD, Sagar KB, Wetherbee JN, Troup PJ. Relationship of left ventricular mass to defibrillation threshold for the implantable defibrillator: A combined clinical and animal study. Am Heart J 1987; 114: 274-278. (Pubitemid 17131721)
32. Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm 2005; 2: 814-819. (Pubitemid 41038399)
33. Dhingra R, Ho Nam B, Benjamin EJ, Wang TJ, Larson MG, D'Agostino RB Sr, et al. Cross-sectional relations of electrocardiographic QRS duration to left ventricular dimensions: The Framingham Heart Study. J Am Coll Cardiol 2005; 45: 685-689. (Pubitemid 40278966)
34. Cohen TJ, Chengot T, Quan C, Peller AP. Elevation of defibrillation thresholds with propofol during implantable cardioverter-defibrillator testing. J Invasive Cardiol 2000; 12: 121-123.